euro adhoc: Intercell AG / Joint Ventures/Cooperation/Collaboration / Collaboration with PATH for the development of Intercell’s Streptococcus pneumoniae vaccine

--------------------------------------------------------------------------------
Disclosure announcement transmitted by euro adhoc.
The issuer is responsible for the content of this announcement.
--------------------------------------------------------------------------------

06.09.2006

» Support from PATH for the development of Intercell's Streptococcus
pneumoniae candidate vaccine - USD 7.3 m initial funding through
preclinical stage, leading to a vaccine candidate ready to enter
clinical trials » Pneumococcus causes pneumonia and sepsis - it is a
major life-threatening pathogen that is a particular risk for
children and the elderly. » Intercell and PATH will develop the
vaccine protecting against the majority of pneumococcal strains
and make it available at an affordable cost for children in
certain developing world countries. Intercell will retain all
rights in developed countries.

Intercell and PATH, a US-based non-profit organization dedicated to
finding solutions for global health issues today announced an
agreement to advance the development of Intercell's Streptococcus
pneumoniae vaccine. Intercell will receive a total of USD 7.3 m
during the first stage of the collaboration, with the potential for
substantial additional funding during later development phases.
Intercell and PATH are committed to work together towards the
successful development of the vaccine in clinical trials leading to
registration and market approval.

PATH will provide funding to support Intercell's ongoing
Streptococcus pneumoniae ("Pneumococcus") protein-based vaccine
development program, facilitating the completion of preclinical work.
This program is derived from Intercell's proprietary antigen
discovery technology, AIP®, and targets a major worldwide cause of
pneumonia, bacterial sepsis and meningitis.

Under the terms of the collaboration, Intercell will develop the
vaccine and make it available at an affordable cost for children in
developing World countries at greatest need, where Pneumococcus is a
major cause of infant and childhood mortality. Worldwide, more than 1
million people die each year from pneumococcal infections; children
under 5 years of age account for the majority of these deaths.
Intercell retains all rights in developed countries for the childhood
formulation of the pneumococcal vaccine and also retains as a key aim
the rights for an adult formulation of the same product, designed to
prevent pneumococcal infection in the elderly. Current vaccines on
the market cover only a limited number of pneumococcal strains,
especially outside the US, and also are not affordable to countries
in the developing World.

"We are delighted that PATH, after an extensive review of the field,
has selected our vaccine as one of the most promising novel
approaches to prevent Streptococcus pneumoniae infection. The
experience and commitment of PATH will be an extremely valuable asset
to Intercell and we look forward to working with the group as we
advance the project towards the clinic", states Gerd Zettlmeissl, CEO
of Intercell AG.

"Intercell’s innovative protein-based vaccine is a promising
candidate for protecting children in the developing world," notes
John Boslego, director of pneumococcal vaccine development at PATH.
"We at PATH are particularly interested in developing a vaccine
containing proteins which are common to all pneumococcus serotypes
because such a ‘common protein’ vaccine could provide broad
protection to children worldwide."

end of announcement euro adhoc 06.09.2006 07:01:21
--------------------------------------------------------------------------------

ots Originaltext: Intercell AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:
Intercell AG
Mag. Katharina Wieser
Head of Corporate Communications
Tel. +43 1 20620-303
kwieser@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Börsen: Wiener Börse AG / official market